

Lorenzo Gerratana

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6373742/lorenzo-gerratana-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

105
papers

1,513
citations

19
h-index

37
g-index

183
ext. papers

2,026
ext. citations

4.4
avg, IF

4.39
L-index

#	Paper	IF	Citations
105	Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis.. <i>Cancer Research</i> , 2022 ,	10.1	5
104	Image Analysis of Circulating Tumor Cells and Leukocytes Predicts Survival and Metastatic Pattern in Breast Cancer Patients.. <i>Frontiers in Oncology</i> , 2022 , 12, 725318	5.3	
103	Abstract P2-02-05: Dynamic circulating tumor cell changes in enumeration and HER2 expression during systemic therapy for metastatic breast cancer. <i>Cancer Research</i> , 2022 , 82, P2-02-05-P2-02-05	10.1	
102	Abstract P2-01-04: ESR1 hotspot mutations in circulating tumor DNA mutation are associated with endocrine therapy resistance in metastatic breast cancer. <i>Cancer Research</i> , 2022 , 82, P2-01-04-P2-01-04	10.1	
101	Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC). <i>Cancer Research</i> , 2022 , 82, P2-07-02-P2-07-02	10.1	
100	Abstract P2-01-08: ESR1 Y537 mutations are associated with increased baseline circulating tumor cells enumeration for patients with estrogen receptor positive metastatic breast cancer. <i>Cancer Research</i> , 2022 , 82, P2-01-08-P2-01-08	10.1	
99	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation.. <i>Oncologist</i> , 2022 ,	5.7	4
98	The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 1361-1370	12.9	5
97	A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1185, 122985	3.2	2
96	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021 , 27, 3443-3455 ²	12.9	
95	Liquid biopsy for baseline evaluation of tumor burden in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A proof of principle study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e13008-e13008	2.2	
94	Refining neutropenia risk assessment in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC) through a cell-free DNA workflow (cfDNA).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1027-1027	2.2	0
93	Landscape of GATA3 mutations identified from circulating tumor DNA clinical testing and their impact on disease outcomes in estrogen receptor-positive (ER+) metastatic breast cancers treated with endocrine therapies.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1065-1065	2.2	1
92	Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2021 , 5, 943-952	3.6	1
91	LDH as prognostic factor in second line treatment for advanced gastric cancer: The LINE study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16102-e16102	2.2	0
90	Uncovering the differential impact of ESR1 and PIK3CA codon variants on the clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1033-1033	2.2	1
89	Correlation between different levels of HER2 expression in circulating tumor cells (cHER2 ratio) and metastatic behavior in stage I/II aggressive breast cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3036-3036 ¹	2.2	1

88	Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	11
87	First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study. <i>Breast</i> , 2021 , 57, 104-112	3.6	2
86	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 82	7.8	0
85	Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 187, 397-405	4.4	3
84	Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study. <i>Clinical Nutrition</i> , 2021 , 40, 286-294	5.9	8
83	CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer. <i>Journal of Pathology</i> , 2021 , 253, 234-245	9.4	3
82	Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools. <i>European Journal of Cancer</i> , 2021 , 143, 147-157	7.5	11
81	Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China. <i>Breast Cancer Research and Treatment</i> , 2021 , 190, 213-226	4.4	
80	Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer.. <i>Cancers</i> , 2021 , 14,	6.6	1
79	Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	12
78	The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020 , 25, 661-668	5.7	6
77	Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study. <i>Future Oncology</i> , 2020 , 16, 2059-2073	3.6	1
76	Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. <i>Scientific Reports</i> , 2020 , 10, 7010	4.9	8
75	Prognostic role of macrophage infiltration and monocyte-to-lymphocyte ratio in stage III colon cancer: The MIRROR study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16118-e16118	2.2	1
74	The landscape of genomic alterations detected in serial circulating tumor DNA (ctDNA) in clinical progressive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1084-1084	2.2	
73	Circulating tumor DNA (ctDNA) to evaluate stage III and stage IV metastatic breast cancer (MBC), describe tumor heterogeneity, and outcome.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1028-1028	2.2	
72	Cell-free DNA comparative analysis of hormone receptor-positive, first-line metastatic breast cancer genomic landscape in the United States and China.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1059-1059	2.2	1
71	Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC). <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 145, 102856	7	12

70	Plasma-Based Longitudinal Evaluation of Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 550185	5.3	4
69	Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. <i>Future Oncology</i> , 2020 , 16, 2645-2660	3.6	1
68	Landscape of circulating tumour DNA in metastatic breast cancer. <i>EBioMedicine</i> , 2020 , 58, 102914	8.8	19
67	The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells. <i>Seminars in Cancer Biology</i> , 2020 , 60, 344-350	12.7	10
66	Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker. <i>Cancers</i> , 2019 , 11,	6.6	17
65	Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. <i>Cancers</i> , 2019 , 11,	6.6	41
64	Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer. <i>Cancers</i> , 2019 , 11,	6.6	8
63	The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019 , 10, 368-377	10.3	36
62	Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	23
61	APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 309	12.8	15
60	Emerging Role of Genomics and Cell-Free DNA in Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2019 , 20, 68	5.4	6
59	Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC)? A network meta-analysis (NMA).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5564-5564	2.2	1
58	Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach. <i>Annals of Translational Medicine</i> , 2019 , 7, 14	3.2	8
57	Role of anthracyclines in neoadjuvant anti-HER2 regimens for HER2+ breast cancer (BC): A network meta-analysis (NMA).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 577-577	2.2	
56	Can the enumeration of circulating tumor cells (CTCs) and the characterization of circulating tumor DNA (ctDNA) provide insight into organ tropism in metastatic breast cancer (MBC)?. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3038-3038	2.2	
55	Association of HER2 alterations and ESR1 mutations in cell-free DNA (cfDNA) with circulating tumor cells (CTCs), multiple metastasis, and prognosis in stage III/IV breast cancer (BCa).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1036-1036	2.2	
54	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919885540	5.4	12
53	Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer. <i>Breast Cancer Research</i> , 2019 , 21, 137	8.3	25

52	Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma. <i>Melanoma Research</i> , 2019 , 29, 510-515	3.3	8
51	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 591-597	3.6	4
50	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 134, 39-45	7	129
49	Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. <i>Cancer Treatment Reviews</i> , 2019 , 73, 73-83	14.4	62
48	Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. <i>Cancer Discovery</i> , 2019 , 9, 96-113	24.4	142
47	Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation. <i>Cancer Treatment Reviews</i> , 2019 , 72, 7-14	14.4	12
46	BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy. <i>International Journal of Cancer</i> , 2019 , 144, 755-766	7.5	36
45	Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. <i>Breast</i> , 2018 , 40, 45-52	3.6	4
44	Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy. <i>Future Oncology</i> , 2018 , 14, 849-859	3.6	13
43	MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme. <i>Future Oncology</i> , 2018 , 14, 699-707	3.6	18
42	Determinants of Last-line Treatment in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018 , 18, 205-213	3.6	7
41	Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study : Complementary and alternative medicine in oncology. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 2029-2047	4.9	5
40	Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2018 , 140, 559-568	4.8	7
39	Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. <i>Cancer Treatment Reviews</i> , 2018 , 68, 102-110	14.4	102
38	Dynamic changes of interleukin 2 (IL-2) and circulating tumor cells (CTCs) in patients with advanced breast cancer (BCa) after systemic therapies.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1090-1090	2.2	1
37	Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e13079-e13079	2.2	2
36	Association of clinical factors and biological subtypes with different Ca15-3 levels in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e24014-e24014	2.2	
35	Perception and opinions of health professionals of an Italian academic hospital about complementary and alternative medicine in oncology.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18865-e18865	2.2	

34	Circulating tumor cells enumeration (CTCs) and circulating tumor DNA (ctDNA): Clinical and molecular features of rapidly progressing Stage IV disease (Stage IVprog).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12040-12040	2.2	
33	Integration of lymphocyte ratios (LRs) and circulating tumor cells (CTCs) characterization: The interplay between immunity and metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12039-12039	2.2	
32	Abstract 1597: Increased circulating tumor cell (CTC) after systemic therapy is associated with younger age in stage III/IV breast cancer patients 2018 ,		2
31	Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations. <i>Melanoma Research</i> , 2018 , 28, 547-554	3.3	6
30	Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 365-374	5.4	23
29	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , 2017 , 13, 2265-2275	3.6	8
28	Androgen receptor in estrogen receptor positive breast cancer: Beyond expression. <i>Cancer Treatment Reviews</i> , 2017 , 61, 15-22	14.4	30
27	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. <i>Oncologist</i> , 2017 , 22, 1463-1469	5.7	17
26	Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. <i>Breast</i> , 2017 , 31, 114-120	3.6	42
25	Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy. <i>Future Oncology</i> , 2017 , 13, 233-248	3.6	2
24	Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis. <i>Oncotarget</i> , 2017 , 8, 112816-112824	3.3	1
23	Setting and timing of end-of-life care in cancer patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e21502-e21502		
22	Determinants of adjuvant chemotherapy use in small luminal-like breast cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e12010-e12010	2.2	
21	A novel MGMT methylation-based prognostic score in patients with glioblastoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2048-2048	2.2	
20	Preliminary results from CAMEO-PRO study: Complementary and alternative medicine in oncology physicians inform oncological patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e21632-e21632	2.2	
19	In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis. <i>Breast Cancer Research</i> , 2016 , 18, 30	8.3	100
18	Risk of unplanned presentations and hospital admission in lung cancer patients: Insights from the experience of a single institution.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21601-e21601	2.2	
17	Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example. <i>OncoTargets and Therapy</i> , 2016 , 9, 5399-404	4.4	1

16	Do platinum salts fit all triple negative breast cancers?. <i>Cancer Treatment Reviews</i> , 2016 , 48, 34-41	14.4	38
15	Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?. <i>Oncologist</i> , 2015 , 20, 719-24	5.7	40
14	Pattern of metastasis and outcome in patients with breast cancer. <i>Clinical and Experimental Metastasis</i> , 2015 , 32, 125-33	4.7	101
13	Endocrine maintenance therapy in luminal breast cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e11578-e11578		
12	Treatment during the last month of life in advanced cancer patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17649-e17649	2.2	
11	Endocrine therapy and chemotherapy in luminal metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e11573-e11573	2.2	
10	Measures of outcome in metastatic breast cancer: insights from a real-world scenario. <i>Oncologist</i> , 2014 , 19, 608-15	5.7	143
9	Factors affecting patient's perception of anticancer treatments side-effects: an observational study. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 139-50	4.1	20
8	Pattern of metastatic spread and prognosis of breast cancer biologic subtypes.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e12532-e12532	2.2	6
7	Differences in hormonal receptor status and Ki67 expression between primary breast cancer and metastasis: Is variation related to previous therapy?. <i>Journal of Clinical Oncology</i> , 2014 , 32, e22006-e22006	2.2	2.2
6	Advanced luminal breast cancer: Who receives chemotherapy as first-line systemic treatment?. <i>Journal of Clinical Oncology</i> , 2014 , 32, e11524-e11524	2.2	
5	Risk factors and survival outcomes in patients with brain metastases from breast cancer. <i>Clinical and Experimental Metastasis</i> , 2013 , 30, 951-6	4.7	23
4	Endocrine therapy in patients with metastatic breast cancers (MBC): Prognosis and measures of outcome.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e13070-e13070	2.2	
3	Tailored endpoints: A proposal for design of future clinical trials in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, e13058-e13058	2.2	
2	Association of body mass index and outcome in advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1044-1044	2.2	
1	Hotspot ESR1 mutations are multimodal and contextual drivers of breast cancer metastasis		1